{
    "root": "362d24c1-c384-4543-e063-6294a90a6b8f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "RASAGILINE",
    "value": "20250528",
    "ingredients": [
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "RASAGILINE MESYLATE",
            "code": "LH8C2JI290",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63620"
        }
    ],
    "indications": {
        "text": "rasagiline tablets indicated treatment parkinson 's disease ( pd ) .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "monotherapy : rasagiline tablet 1 mg daily ( 2.1 ) adjunct without levodopa : rasagiline tablet 1 mg daily ( 2.1 ) adjunct levodopa : rasagiline tablet 0.5 mg daily . increase dose 1 mg daily needed sufficient response ( 2.1 ) patients taking ciprofloxacin cyp1a2 inhibitors : rasagiline tablet 0.5 mg daily ( 2.2 , 5.4 ) patients mild hepatic impairment : rasagiline tablet 0.5 mg daily . rasagiline tablet used patients moderate severe hepatic impairment ( 2.3 , 5.5 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "rasagiline 0.5 mg tablets : white off-white , circular , flat faced beveled edge , uncoated tablets , debossed \u201c 0.5 \u201d one face plain side containing , active ingredient , rasagiline mesylate equivalent 0.5 mg rasagiline base . bottles 30 ndc 42571-220-30 bottles 500 ndc 42571-220-05 bottles 1000 ndc 42571-220-10 rasagiline 1 mg tablets : white off-white , circular , flat faced beveled edge , uncoated tablets , debossed \u201c 1 \u201d one face plain side containing , active ingredient , rasagiline mesylate equivalent 1 mg rasagiline base . bottles 30 ndc 42571-221-30 bottles 500 ndc 42571-221-05 bottles 1000 ndc 42571-221-10 storage : store 25\u00b0c ( 77\u00b0f ) excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) . [ usp controlled room temperature ] .",
    "adverseReactions": "rasagiline tablet contraindicated meperidine , tramadol , methadone , propoxyphene , mao inhibitors ( maois ) , including selective mao-b inhibitors , risk serotonin syndrome [ ( 5.2 ) ] . least 14 days elapse discontinuation rasagiline tablet initiation treatment medications . rasagiline tablet contraindicated st. john \u2019 wort cyclobenzaprine . rasagiline tablet contraindicated dextromethorphan risk episode psychosis bizarre behavior .",
    "indications_original": "Rasagiline tablets are indicated for the treatment of Parkinson's disease (PD).",
    "contraindications_original": "Monotherapy: Rasagiline tablet 1 mg once daily ( 2.1 ) As adjunct without levodopa: Rasagiline tablet 1 mg once daily ( 2.1 ) As adjunct to levodopa: Rasagiline tablet 0.5 mg once daily. Increase dose to 1 mg daily as needed for sufficient clinical response ( 2.1 ) Patients taking ciprofloxacin or other CYP1A2 inhibitors: rasagiline tablet 0.5 mg once daily ( 2.2 , 5.4 ) Patients with mild hepatic impairment: Rasagiline tablet 0.5 mg once daily. Rasagiline tablet should not be used in patients with moderate or severe hepatic impairment ( 2.3 , 5.5 )",
    "warningsAndPrecautions_original": "Rasagiline 0.5 mg Tablets:\n                  \n                  White to off-white, circular, flat faced beveled edge, uncoated tablets, debossed with \u201c0.5\u201d on one face and plain on the other side containing, as the active ingredient, rasagiline mesylate equivalent to 0.5 mg of rasagiline base.\n                  \n                  Bottles of 30 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 42571-220-30\n                  Bottles of 500\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 42571-220-05\n                  Bottles of 1000\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 42571-220-10\n                  \n                  Rasagiline 1 mg Tablets:\n                  \n                  White to off-white, circular, flat faced beveled edge, uncoated tablets, debossed with \u201c1\u201d on one face and plain on the other side containing, as the active ingredient, rasagiline mesylate equivalent to 1 mg of rasagiline base.\n                  \n                  Bottles of 30 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 42571-221-30\n                  Bottles of 500\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 42571-221-05\n                  Bottles of 1000 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 42571-221-10\n                  \n                       Storage: \n  \n                  \n                  Store at 25\u00b0C (77\u00b0F) with excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F).[see USP Controlled Room Temperature].",
    "adverseReactions_original": "Rasagiline tablet is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome\n \n  [see\n  \n   Warnings and Precautions (5.2)]\n \n  . At least 14 days should elapse between discontinuation of rasagiline tablet and initiation of treatment with these medications.\n\n \n                  \n                  Rasagiline tablet is contraindicated for use with St. John\u2019s wort and with cyclobenzaprine.\n                  \n                  Rasagiline tablet is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior.",
    "drug": [
        {
            "name": "RASAGILINE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63620"
        }
    ]
}